<DOC>
	<DOCNO>NCT02137109</DOCNO>
	<brief_summary>The primary objective study evaluate safety natalizumab use pediatric multiple sclerosis ( MS ) population .</brief_summary>
	<brief_title>Safety Efficacy Pediatric MS Patients Prescribed Tysabri</brief_title>
	<detailed_description>All available retrospective prospective data pediatric MS participant receive least 1 dose natalizumab turn 18 year old 31Mar2015 use study . Prospective data define data collect future , i.e. , new participant include first data transfer additional data exist participant include first data transfer . Existing biospecimen sample evaluate collected part study .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Key All available retrospective prospective data pediatric MS patient receive least 1 dose natalizumab turn 18 year old 31 March 2015 . In addition , patient must register TOUCH ( US patient ) , enrol Biogen sponsor postmarketing observational study ( e.g. , TOP ( NCT00493298 ) TYGRIS ( NCT00477113 , NCT00483847 ) ) , countryspecific TYSABRI registry . Adequate data receive Biogen 30 September 2015 use metaanalysis include data collect patient may turn 18 year old . Key Data receive Biogen 30 September 2015 include statistical analysis NOTE : Other protocoldefined inclusion/exclusion Criteria May Apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Pediatric</keyword>
</DOC>